366074
Alternative Names: TA-1702Latest Information Update: 13 Jun 2023
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Developer GSK
- Class
- Mechanism of Action Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Overactive bladder
Most Recent Events
- 25 May 2010 Discontinued - Phase-I for Overactive bladder in USA (unspecified route)
- 01 Oct 2007 Tanabe Seiyaku Co. Ltd has merged with Mitsubishi Pharma Corporation to form Mitsubishi Tanabe Pharma Corporation
- 30 Sep 2007 Suspended - Phase-I for Overactive bladder in USA (unspecified route)